Economics at your fingertips  

“Shall We Dance?†– Biologic-Biosimilar Competition Under the Biologics Price Competition and Innovation Act

Gregory Asciolla and Matthew Perez

Antitrust Chronicle, 2015, vol. 12

Abstract: It remains to be seen whether a settlement in the context of biologics patent litigation will ultimately trigger the same competitive concerns that patent settlements in the Hatch-Waxman context have often triggered. Gregory S. Asciolla & Matthew J. Perez (Labaton Sucharow LLP)

JEL-codes: K21 (search for similar items in EconPapers)
Date: 2015
References: Add references at CitEc
Citations: Track citations by RSS feed

Downloads: (external link) ... n-and-innovation-act (application/pdf)
Requires login and subscription

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link:

Access Statistics for this article

More articles in Antitrust Chronicle from Competition Policy International
Bibliographic data for series maintained by Lindsay McSweeney (). This e-mail address is bad, please contact .

Page updated 2019-04-21
Handle: RePEc:cpi:atchrn:12.1.2015:i=20749